Immuneering Corporation
IMRXHealthcare|Biotechnology|US
$3.68
+0.31 (+9.20%)
DCF Value
$2.80
Tangible Book / Share
$2.50
Cash / Share
$2.25
Clinical Trials (3)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07562152 Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | Pancreatic Cancer, Pancreatic Cancer Metastatic | P3 | Recruiting | 570 | RCT, Open-label | Atebimetinib, GnP, mGnP |
| NCT05585320 A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | Advanced Solid Tumor, Pancreatic Adenocarcinoma | P1P2 | Active | 209 | Open-label | IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + modified FOLFIRINOX (Treatment Group C), IMM-1-104 + dabrafenib (Treatment Group D), IMM-1-104 + pembrolizumab (Treatment Group E) |
| NCT06208124 A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma | P1P2 | Completed | 30 | Open-label | IMM-6-415 |